| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |